Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

Joshua J Neumiller1, Travis E Sonnett2, Lindy D Wood1, Stephen M Setter1, R Keith Campbell21Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; 2Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Joshua J Neumiller, Travis E Sonnett, Lindy D Wood, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/26efd2116d4d480b81b6ec46dc6d597a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26efd2116d4d480b81b6ec46dc6d597a
record_format	dspace
spelling	oai:doaj.org-article:26efd2116d4d480b81b6ec46dc6d597a2021-12-02T00:25:46ZPharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes1178-7007https://doaj.org/article/26efd2116d4d480b81b6ec46dc6d597a2010-07-01T00:00:00Zhttp://www.dovepress.com/pharmacology-efficacy-and-safety-of-liraglutide-in-the-management-of-t-a4835https://doaj.org/toc/1178-7007Joshua J Neumiller1, Travis E Sonnett2, Lindy D Wood1, Stephen M Setter1, R Keith Campbell21Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; 2Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USAAbstract: Liraglutide is a glucagon-like peptide-1 analog with pharmacokinetic properties suitable for once-daily administration approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes. Clinical trial data from large, controlled studies &shy;demonstrate the safety and efficacy of liraglutide in terms of hemoglobin A1c (HbA1c) reduction, reductions in body weight, and the drug&rsquo;s low risk for hypoglycemic events when used as monotherapy. &shy;Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and &shy;rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase III trials. Once-daily &shy;administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in HbA1c and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with incretin analog therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications. Data to date on patient-reported outcomes with liraglutide treatment are encouraging. The most common adverse events associated with liraglutide therapy are dose-dependent nausea, vomiting, and diarrhea. Diligent postmarketing surveillance to elucidate the risk of pancreatitis and medullary thyroid carcinoma in a heterogeneous population are likely warranted.Keywords: incretin analog, incretin effect, liraglutide, diabetes Joshua J NeumillerTravis E SonnettLindy D Woodet alDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 215-226 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Joshua J Neumiller Travis E Sonnett Lindy D Wood et al Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
description	Joshua J Neumiller1, Travis E Sonnett2, Lindy D Wood1, Stephen M Setter1, R Keith Campbell21Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; 2Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USAAbstract: Liraglutide is a glucagon-like peptide-1 analog with pharmacokinetic properties suitable for once-daily administration approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes. Clinical trial data from large, controlled studies &shy;demonstrate the safety and efficacy of liraglutide in terms of hemoglobin A1c (HbA1c) reduction, reductions in body weight, and the drug&rsquo;s low risk for hypoglycemic events when used as monotherapy. &shy;Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and &shy;rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase III trials. Once-daily &shy;administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in HbA1c and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with incretin analog therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications. Data to date on patient-reported outcomes with liraglutide treatment are encouraging. The most common adverse events associated with liraglutide therapy are dose-dependent nausea, vomiting, and diarrhea. Diligent postmarketing surveillance to elucidate the risk of pancreatitis and medullary thyroid carcinoma in a heterogeneous population are likely warranted.Keywords: incretin analog, incretin effect, liraglutide, diabetes
format	article
author	Joshua J Neumiller Travis E Sonnett Lindy D Wood et al
author_facet	Joshua J Neumiller Travis E Sonnett Lindy D Wood et al
author_sort	Joshua J Neumiller
title	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_short	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_full	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_fullStr	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_full_unstemmed	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_sort	pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/26efd2116d4d480b81b6ec46dc6d597a
work_keys_str_mv	AT joshuajneumiller pharmacologyefficacyandsafetyofliraglutideinthemanagementoftype2diabetes AT travisesonnett pharmacologyefficacyandsafetyofliraglutideinthemanagementoftype2diabetes AT lindydwood pharmacologyefficacyandsafetyofliraglutideinthemanagementoftype2diabetes AT etal pharmacologyefficacyandsafetyofliraglutideinthemanagementoftype2diabetes
_version_	1718403729467637760

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

Ejemplares similares